Pharmadrug (TSE:PHRX) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PharmaDrug’s Sairiyo Therapeutics has successfully completed a stability study of its reformulated cepharanthine, PD-001, paving the way for its Phase 1 clinical trial as a potential treatment for viral infectious diseases. This development marks a significant step forward in leveraging cepharanthine’s improved oral bioavailability for more effective therapeutic applications. The completion of the study allows the company to proceed with manufacturing and clinical trial preparations in Australia.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.